• VEGFC–VEGFR-3 Axis in NASH Fibrosis: Inhibition by Naringin

  2026-05-18

  This study elucidates how naringin protects against high-fat diet-induced hepatic fibrosis by disrupting the VEGFC-mediated hepatocyte-macrophage regulatory axis. The work demonstrates, through both genetic and pharmacological VEGFR-3 inhibition, that modulating this pathway reduces liver inflammation and fibrosis, providing a mechanistic rationale for targeted anti-lymphangiogenic interventions in NASH.

• Plant Exosome-like Nanovesicles Reverse Sertoli Cell Cycle A

  2026-05-18

  This study demonstrates that exosome-like nanovesicles from Cistanche deserticola (CDELNs) can alleviate cyclophosphamide-induced testicular injury by targeting the cell cycle inhibitor P21 in Sertoli cells. The findings highlight a novel, mechanistically defined approach to restoring male reproductive function following chemotherapy-induced damage.

• AGO1’s RNA-Independent Role in Stem Cell Fate via Protein Fo

  2026-05-17

  Liu et al. reveal a novel, RNA-independent function for AGO1 in maintaining mouse embryonic stem cell stemness through regulation of protein folding, distinguishing its activity from AGO2. This insight redefines our understanding of Argonaute proteins in cell fate determination and opens avenues for dissecting non-canonical regulatory mechanisms in stem cell biology.

• PD 173074: Advancing FGFR Signaling Pathway Inhibition in Re

  2026-05-16

  PD 173074 delivers precise, nanomolar-selective FGFR1 and VEGFR2 inhibition, empowering researchers to dissect FGF-dependent processes from neuron survival to cancer cell proliferation. Its robust selectivity and proven performance in both in vitro and in vivo models make it the go-to tool for targeted pathway analysis and resistance reversal.

• Fluconazole as a Precision Probe: Advanced Insights for Anti

  2026-05-15

  Explore how Fluconazole, a fungal cytochrome P450 enzyme 14α-demethylase inhibitor, powers next-generation antifungal mechanism studies and resistance modeling. This article delivers advanced, evidence-based guidance distinct from existing resources.

• Latrunculin B Inhibitor: Precision Disruption of Actin Dynam

  2026-05-15

  Latrunculin B enables rapid, reversible, and highly specific actin cytoskeleton disruption for advanced cellular dynamics studies. Its transient action, purity, and integration into optimized workflows make it indispensable for researchers demanding temporal control and reproducibility. Discover how APExBIO’s Latrunculin B (SKU C5804) empowers robust assay design and troubleshooting in cytoskeletal research.

• PD0325901: Precision MEK Inhibition and Pathway Vulnerabilit

  2026-05-14

  Explore the advanced molecular action of PD0325901, a selective MEK inhibitor, and discover how recent insights into genome folding dynamics refine its role in cancer research. This article provides deeper context for assay optimization and pathway vulnerability.

• Hypoxia-Induced Cognitive Impairment: Choroid Plexus and AMP

  2026-05-14

  This study elucidates how hypoxic exposure disrupts the choroid plexus barrier and promotes M1 macrophage polarization via aberrant AMPK signaling, leading to cognitive impairment in mice. The mechanistic cascade revealed offers new targets for intervention strategies against hypoxia-related CNS dysfunction.

• SAR131675 as a VEGFR-3 Inhibitor: New Insights for Lymphatic

  2026-05-13

  Explore the distinctive scientific and experimental value of SAR131675 as a VEGFR-3 inhibitor. This article provides a unique, protocol-focused view on its anti-lymphangiogenic mechanisms and practical implications beyond tumor models.

• High-Fidelity PCR as a Pillar for Next-Gen Immunotherapy Res

  2026-05-13

  This thought-leadership article examines the pivotal role of high-fidelity PCR—anchored by the innovative 2X HyperFusion™ High-Fidelity Master Mix—in enabling translational breakthroughs in immuno-oncology. By integrating mechanistic insights, real-world protocol guidance, and analysis of strategic opportunities, we reveal how advanced PCR technologies are shaping the future of immunogenomics and CRISPR-based therapeutics.

• ATRX-Deficient Glioma Sensitivity to RTK/PDGFR Inhibitors: I

  2026-05-12

  This study identifies ATRX-deficient high-grade glioma cells as highly sensitive to multi-targeted RTK and PDGFR inhibitors, suggesting ATRX status as a key biomarker for targeted therapy. The findings have significant implications for stratifying patients in clinical trials and optimizing combinatorial treatment strategies.

• ETS1-SENP2 Axis Regulates Mitophagy in Bronchopulmonary Dysp

  2026-05-12

  This study reveals how ETS1 suppresses mitochondrial damage-induced autophagy in bronchopulmonary dysplasia (BPD) by modulating the SENP2/HSPA8/FUNDC1 axis. By detailing the molecular mechanism of sumoylation-dependent mitophagy regulation, the findings offer new insights for targeted interventions in BPD and related mitochondrial disorders.

• Nintedanib (BIBF 1120): Expanding Frontiers in Translational

  2026-05-11

  This article examines the mechanistic depth and strategic potential of Nintedanib (BIBF 1120) as a triple angiokinase inhibitor in cancer and fibrosis research. Blending evidence from recent studies—particularly in ATRX-deficient high-grade glioma—with actionable guidance, it charts new translational opportunities, contextualizes competitive differentiation, and provides protocol insights for researchers aiming to leverage antiangiogenic agents for next-generation therapy.

• Dorsomorphin (Compound C): Precision AMPK Inhibition in Meta

  2026-05-11

  Dorsomorphin (Compound C) from APExBIO enables targeted inhibition of AMPK and BMP pathways, empowering researchers to dissect metabolic rewiring, autophagy, and differentiation with high selectivity. This guide details advanced workflows, troubleshooting strategies, and actionable protocol parameters, delivering robust control for complex cell and animal models.

• PP2A Regulation of Autophagy Drives Candida albicans Drug Re

  2026-05-10

  This study reveals that protein phosphatase 2A (PP2A) modulates autophagy via ATG protein phosphorylation, directly influencing biofilm formation and antifungal drug resistance in Candida albicans. These findings highlight autophagy as a pivotal mechanism in biofilm-associated resilience, suggesting new strategies for managing antifungal resistance.

479 records 13/32 page Previous Next First page 上5页 1112131415 下5页 Last page